Welcome to our dedicated page for Biodexa Pharmaceuticals news (Ticker: BDRX), a resource for investors and traders seeking the latest updates and insights on Biodexa Pharmaceuticals stock.
Biodexa Pharmaceuticals plc reports news on a clinical-stage biopharmaceutical pipeline focused on gastrointestinal cancers, rare diseases and other unmet medical needs. The company’s programs include eRapa for familial adenomatous polyposis and non-muscle invasive bladder cancer, MTX240, a molecular glue candidate for gastrointestinal stromal tumors, and tolimidone for type 1 diabetes.
Recurring developments cover clinical development, regulatory and trial authorizations, manufacturing and access partnerships, licensing, annual results, financing activity, ADR program matters and patient-advocacy initiatives. Biodexa’s American depositary shares trade under BDRX, while company updates may also describe ordinary-share and ADR mechanics for the U.K. issuer.
Biodexa Pharmaceuticals (Nasdaq: BDRX)/b) announced voting outcomes from its re-scheduled Annual General Meeting held on June 30, 2026.Ordinary resolutions 1–7 passed with majorities between 73% and 94%. Ordinary resolution 8, special resolution 10, and contingent resolution 11 did not pass.
Biodexa Pharmaceuticals (Nasdaq: BDRX) priced equity financings totaling approximately $3.5 million, including a registered direct offering, a concurrent private placement of pre-funded warrants, and a warrant inducement transaction.
The offerings, at an exercise/offer price of $2.85 per ADS, are expected to close around July 1, 2026, with net proceeds intended for development programs, working capital and general corporate purposes.
Biodexa (Nasdaq: BDRX) received approval from Health Canada to expand its registrational Serenta Phase 3 trial in familial adenomatous polyposis (FAP) into Canada.
The study is recruiting in 29 centers across the US and Europe, with Canada expected to add 3–4 sites. Serenta plans to enroll 168 patients; 73 are enrolled to date.
Biodexa Pharmaceuticals (Nasdaq: BDRX), a clinical-stage biopharmaceutical company focused on gastrointestinal cancers, adjourned its Annual General Meeting on June 17, 2026 due to lack of quorum.
The AGM is re-scheduled for 11:00am BST on June 30, 2026 at the company’s Cardiff offices, and previously submitted proxies remain valid.
Biodexa Pharmaceuticals (Nasdaq: BDRX) has issued a shareholder letter outlining proposals to reorganize its share capital at the June 17, 2026 AGM.
The plan includes a 10,000:1 reverse split of 373,056,808,922 ordinary shares into 37,305,681, creation of E deferred shares, and changing the ordinary share/ADS ratio from 500,000:1 to 50:1, keeping approximately 746,113 ADSs and shareholder rights and ownership percentages unchanged.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced a partnership with Syngene to manufacture GMP clinical trial supplies of MTX240, covering both the active pharmaceutical ingredient and dosage form.
According to the company, Syngene previously manufactured tolimidone on time and on budget and, following Biodexa's MTX240 license from Otsuka in early February, designed a GMP program within a few weeks.
Biodexa (Nasdaq: BDRX) and Tanner Pharma Group launched a global Early Access / Named Patient Program for eRapa to treat Familial Adenomatous Polyposis (FAP) on March 31, 2026. The program enables clinicians to prescribe investigational oral rapamycin capsules outside clinical trials where local regulations permit.
The initiative aims to expand access, provide compliant, controlled supply in countries where eRapa is not available, and collect Real World Data (RWD) to improve understanding of FAP and patient experience. Access depends on patient eligibility, local laws, and funding availability.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced audited preliminary results for the year ended 31 December 2025. The company is a clinical-stage biopharmaceutical focused on treatments and prevention for gastrointestinal cancers. Contact details provided include CEO Stephen Stamp and CFO Fiona Sharp.
The announcement confirms the availability of audited preliminary results and directs stakeholders to Biodexa for further information.
Biodexa (Nasdaq: BDRX) has launched a global Early Access Program for its investigational medicine eRapa to treat Familial Adenomatous Polyposis (FAP) patients via a strategic partnership with Tanner Pharma Group.
The program enables clinicians worldwide to prescribe eRapa outside clinical trials, subject to local laws and funding, and Biodexa will collect Real World Data to better understand FAP patient experiences.
Biodexa Pharmaceuticals (Nasdaq: BDRX) announced an ADR ratio change from 1 ADR = 100,000 ordinary shares to 1 ADR = 500,000 ordinary shares, effective on or about April 6, 2026. ADR holders must surrender five old ADRs for one new ADR (New CUSIP: 59564R872).
The change will operate as a one-for-five reverse ADR split for ADRs only; ordinary shares are not affected. The depositary, JP Morgan Chase Bank, N.A., will manage exchanges and sell any aggregate fractional interests, distributing net proceeds. The Company said the change aims to comply with Nasdaq's $1.00 minimum bid requirement but gave no assurance it will achieve that outcome.